Arrowhead Research Corp.
225 South Lake Avenue
Suite 1050
Pasadena,
CA 91101
United States - Map
Phone: 626-304-3400
Fax: 626-304-3401
Website: http://www.arrowheadresearch.com
Arrowhead Research Corporation operates as a clinical stage therapeutics company. It has development programs in oncology, obesity, and chronic hepatitis B virus (HBV) infection. The company assembles a set of technologies, including Dynamic Polyconjugate platform, a RNA delivery system that addresses multiple organ systems and cell types, promotes multi-log gene knockdown in rodents and non-human primates, and induces endosomal escape; and RONDEL, a RNA delivery system for systemic siRNA delivery, and RNAi-mediated mRNA and protein knockdown in human melanoma patients. It also offers Homing Peptides platform, a library of short peptides for the development of peptide-drug conjugates and companion diagnostics. The companys principal product candidates include Adipotide, an anti-obesity peptide, which is in Phase I clinical trial for disrupting the blood supply that supports unhealthy fat by the targeted induction of apoptosis (cell death) in the vasculature of adipose tissue; ARC-520, an RNAi-based therapeutic to treat chronic HBV infection; and CALAA-01, an RNAi-based therapeutic that has completed a Phase IB clinical trial, which targets solid tumors. Its products also comprise CRLX-101 for NSC lung cancer; and Tubulin Inhibitor for oncology. The company, formerly known as InterActive Group, Inc., was founded in 2003 and is headquartered in Pasadena, California. Key Statistics
| |
| | Pay | Exercised | Dr. Christopher R. Anzalone Ph.D.,
44
Chief Exec. Officer, Pres, Director, Chief Exec. Officer of Calando, Chief Exec. Officer of Tego, Chief Exec. Officer of Nantope, Chief Exec. Officer of Leonardo and Chief Exec. Officerablaris Therapeutics | 673.00K | 0.00 | Mr. Kenneth A. Myszkowski CPA,
47
Chief Financial Officer and Principal Accounting Officer | 331.00K | 0.00 | Dr. Bruce D. Given M.D.,
59
Chief Operating Officer and Director of Calando | 326.00K | 0.00 | Mr. Edward W. Frykman ,
77
Director, Chairman of Audit Committee, Member of Nomination Committee, Member of Compensation Committee, Director of Insert Therapeutics Inc, Director of Unidym, Director of Aonex and Director of Calando | 33.00K | N/A | Dr. Mauro Ferrari Ph.D.,
54
Director, Member of Nomination Committee and Member of Compensation Committee | 0.00 | N/A |
|
| | Amounts are as of Dec 30, 2012 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year. | | Currency in USD. |
|
0.01(0.51%) 3:59PM EDT